6Bondaryk M, Kurz tkowski W, Staniszewska M. Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development [ J ]. Postepy Dermatol Alergol,2013,30(5) :293.
7Falci DR,Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections [ J ]. Infect Drug Resist,2013 (6) :163-174.
8Robbins N, Uppuluri P, Nett J, et al. Hsp90 governs dispersion and drug resistance of fungal biofilms [ J ]. PLoS Pathog, 2011, 7 (9) :e1002257.
9Pozzilli P, Leslie RD. Infections and diabetes: Mechanisms and prospects for prevention [ J]. Diabet Med, 1994, 11 (10) :935 -941.
10Rao DD, Desai A, Kulkarni RD, et al. Comparison of max- illofacial space infection in diabetic and nondiabetic patients [ J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 110(4) :e7 -12.
